Leadership Changes - Eldorado Gold Corporation announced the appointment of Simon Hille as Executive Vice President and Chief Operating Officer, effective immediately [2][3] - Gordana Vicentijevic has been appointed as Senior Vice President, Projects, effective May 4, 2026 [5] Simon Hille's Background - Simon Hille joined Eldorado in 2020 and has held progressively senior roles, most recently as Executive Vice President, Technical Services & Operations since November 2023 [3] - He has over 30 years of experience in gold and base metals, with expertise in leading technical and operational teams [4] Gordana Vicentijevic's Background - Gordana Vicentijevic brings 28 years of experience in mining operations, project management, and engineering design from her previous role at Equinox Gold [5] - She holds a Bachelor of Science in Mechanical Engineering (Mining) and a Master's Degree in Engineering Management [5] Strategic Focus - The leadership updates aim to reinforce operational discipline and project execution, enhancing accountability and integration between regional performance and corporate strategy [6] - The appointments are expected to support the continued delivery of Eldorado's strategic priorities [6]

Core Viewpoint - XORTX Therapeutics Inc. has received shareholder approval to consolidate its common shares to comply with NASDAQ listing requirements, specifically to ensure shares trade above $1.00 by April 13, 2026 [1][2] Share Consolidation Details - The consolidation will be on a basis of up to five pre-consolidation common shares for every one post-consolidation common share [1] - Currently, there are 6,962,218 common shares issued and outstanding, which will reduce to approximately 1,392,443 shares post-consolidation, depending on the handling of fractional shares [3] - No fractional common shares will be issued; they will either be canceled or rounded up to the nearest whole number [3] Trading and Shareholder Instructions - If approved by the TSX Venture Exchange, trading on a post-consolidation basis will commence on a date to be determined [4] - Registered shareholders will receive a letter of transmittal with instructions for exchanging their share certificates, while beneficial shareholders will not need to take action [4] Company Overview - XORTX is focused on developing therapies for gout and progressive kidney disease, with three advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [5] - The company is also developing XRx-225 for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [5]

Core Viewpoint - Harrow has announced a private offering of $50 million in senior unsecured notes due 2030, aimed at supporting general corporate purposes and growth initiatives [1][3]. Group 1: Offering Details - The offering consists of $50 million aggregate principal amount of 8.625% senior unsecured notes due September 15, 2030 [1][2]. - The notes will be issued as additional notes under the same indenture as the existing $250 million 2030 notes issued on September 12, 2025, and will be treated as a single series [2]. - The offering price for the new notes is set at 100.25% of the principal amount plus accrued interest from March 15, 2026 [2]. Group 2: Use of Proceeds - The net proceeds from the issuance will be utilized for general corporate purposes, including growth initiatives, product development, and strategic business opportunities [3]. Group 3: Company Overview - Harrow is a leading provider of ophthalmic disease management solutions in North America, focusing on a range of eye conditions [7]. - The company is committed to delivering safe, effective, and affordable medications to enhance patient compliance and improve clinical outcomes [7].

Core Insights - Bright Mountain Media, Inc. reported a full-year revenue of $59.2 million for 2025, an increase of $2.5 million or 4% compared to $56.7 million in 2024 [1][5] - The fourth quarter revenue was $15.7 million, a decrease of $1.4 million or 8% from $17.1 million in Q4 2024, attributed to broader industry challenges including inflation and cautious advertiser spending [2][6] - The advertising technology division was a primary growth driver, with revenue gains largely due to attracting top-tier advertisers and onboarding premium publishers [2][5] Financial Performance - For the year ended December 31, 2025, advertising technology revenue was approximately $21.7 million, digital publishing revenue was approximately $1.5 million, consumer insights revenue was approximately $26.6 million, and creative services revenue was approximately $8.5 million [5][7] - Cost of revenue for the year was $43.4 million, an increase of $3.2 million or 8% compared to $40.2 million in 2024 [7] - General and administrative expenses decreased by 41% to $3.8 million in Q4 2025 from $6.4 million in Q4 2024 [6][10] - The net loss for Q4 2025 was $3.3 million, an improvement of 13% compared to a net loss of $3.8 million in Q4 2024 [6][11] Operational Highlights - The advertising technology division's proprietary platform connects premium advertisers with high-quality Connected TV inventory, leading to increased ad volume and improved rate performance [3] - The company has built a growing network of reputable publishers and streaming partners, contributing to sustainable revenue growth [3] - The overall financial trajectory remains positive despite the challenges faced in the broader market [2]

Core Insights - Draganfly Inc. reported a 17.8% increase in total revenue for fiscal 2025, reaching $7,731,163, with a notable 28.0% rise in product sales [4][6] - The company experienced a comprehensive loss of $22,979,770 for the year, compared to a loss of $14,062,534 in 2024, primarily due to increased operational expenses [4][6] - A strategic defense partnership with Global Ordnance was announced, enhancing Draganfly's position in U.S. defense procurement [4][8] Financial Highlights for 2025 - Total revenue for 2025 was $7,731,163, up 17.8% from $6,561,055 in 2024 [4][6] - Product sales increased by $1,501,339, from $5,368,476 in 2024 to $6,869,815 in 2025 [4] - Services revenue decreased by $331,231, or 27.7%, from $1,192,579 in 2024 to $861,348 in 2025 [4] Operational Highlights for Q4 2025 - Fourth quarter revenue was $1,912,199, an 18.5% increase from $1,613,162 in Q4 2024 [4][9] - Gross profit for Q4 2025 was $85,709, down from $215,740 in Q4 2024, largely due to a non-cash inventory write-down of $244,000 [4][9] - The comprehensive loss for Q4 2025 was $9,371,420, compared to a loss of $4,715,931 in Q4 2024 [4][9] Strategic Developments - Draganfly secured a second major order from a Fortune 50 telecommunications company for its NDAA-compliant heavy-lift drone fleet, indicating strong demand [8] - The company showcased its Outrider Southern Border multi-mission drone at a border security summit, demonstrating its capabilities to U.S. law enforcement [8] - A collaboration with Palladyne AI was announced to integrate advanced autonomy and swarming capabilities into UAV platforms [4][8] Shareholder Information - The company will hold a shareholder update call on March 24, 2026, at 2:30 p.m. PDT / 5:30 p.m. EDT [5]

Core Points - Air Canada provided an update regarding the accident involving Air Canada Express flight AC8646, which occurred on March 22, 2026, at New York LaGuardia, carrying 72 passengers and four crew members [1] - The Captain and First Officer of the flight tragically lost their lives in the accident [2] - Air Canada expressed deep condolences to the families and friends of the deceased pilots and emphasized support for affected passengers and crew members [3] Passenger and Crew Status - Out of the 76 individuals on board, 39 were sent to hospitals with varying degrees of injuries, while 35 did not require immediate medical attention and were able to continue to their final destination [4] - Currently, six individuals remain hospitalized [4] Investigation and Support - Air Canada and Jazz Aviation are cooperating with the Transportation Safety Board of Canada and the National Transportation Safety Board in the investigation of the incident [5] - Family and friends seeking information about passengers on flight AC8646 can contact Air Canada at 1-800-961-7099 [5]

Core Viewpoint - Eagle Bancorp has nominated Trevor Montano to its Board of Directors, bringing extensive investment and banking experience to support the company's strategic initiatives and shareholder value [1][3]. Group 1: Nomination and Board Composition - Trevor Montano is an accomplished investor and public company director with over 20 years of experience in the financial services sector [2][5]. - The Board's nomination of Montano is part of an ongoing refreshment process that began in 2025, which has also included the appointments of Kris Pederson and Ted Wilm [4]. - The Board aims to maintain a balanced mix of skills and experience to effectively address the company's risks and opportunities [4]. Group 2: Montano's Background and Expertise - Montano is the Founder and Managing Member of West Potomac Capital LLC, focusing on financial services investments [2][5]. - He previously served as the Chief Investment Officer at the U.S. Department of the Treasury, managing approximately $5 billion in investments in financial institutions [6][7]. - Montano has completed over 30 strategic M&A and capital raising transactions worth more than $35 billion [5]. Group 3: Company Overview - Eagle Bancorp is the holding company for EagleBank, which operates in the Washington, D.C. area and focuses on building relationships with businesses and individuals [9]. - The bank has been operational since 1998 and has a commitment to a culture of respect, opportunity, belonging, and inclusion [9].

Core Insights - Arq, Inc. is participating in the Water Tower Research Fireside Chat Series on March 25, 2026, at 11:00 AM Eastern Standard Time, with CEO Bob Rasmus representing the company [1][2]. Company Overview - Arq, Inc. (NASDAQ: ARQ) is a diversified environmental technology company focused on producing activated carbon and other environmentally efficient carbon products aimed at purification and sustainable materials [1][3]. - The company is the only vertically integrated producer of activated carbon products in North America, ensuring a reliable domestic supply of innovative and high-demand products [3]. - Arq leverages its expertise to develop solutions that effectively remove harmful chemicals and pollutants from water, land, and air, contributing to a cleaner and safer planet [3].

Core Viewpoint - Li Bang International Corporation Inc. plans to implement a reverse share split of its ordinary shares on a 1-for-100 basis to comply with Nasdaq Marketplace Rule 5550(a)(2) regarding minimum bid price requirements [1][2]. Group 1: Reverse Share Split Details - The reverse share split has been approved by both the shareholders and the board of directors [2]. - Currently, there are 180,401,932 Class A ordinary shares issued and outstanding, which will be consolidated into one Class A ordinary share for every 100 shares held [3]. - The par value of the Class A and Class B ordinary shares will increase from USD 0.0001 to USD 0.01 following the reverse split [3]. - Any fractional shares resulting from the reverse split will be rounded up to the next whole number, ensuring no fractional shares are issued [3]. Group 2: Company Overview - Li Bang International specializes in the design, development, production, and sale of stainless steel commercial kitchen equipment in China [4]. - The company offers comprehensive services, including early-stage design, equipment installation, and after-sales maintenance [4]. - Li Bang aims to become a leading manufacturer of commercial kitchen appliances in China, with a long-term vision of establishing its brand as a household name [4].

Core Viewpoint - DBV Technologies has been admitted to the CAC Mid 60 and SBF 120 Indices, reflecting recognition of its progress in the biopharmaceutical sector and aiming to enhance visibility among investors as it prepares for commercialization [1][2]. Group 1: Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3]. - The company is investigating the use of its proprietary VIASKIN® patch technology, which aims to address food allergies through epicutaneous immunotherapy (EPIT) [3]. - DBV Technologies is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for its VIASKIN Peanut product targeting peanut allergic toddlers and children [3]. Group 2: Market Indices Information - The CAC Mid 60 Index tracks the 60 most actively traded mid-cap French companies, while the SBF 120 Index includes all companies in the CAC Large 60 and CAC Mid 60 Indices [2]. - Inclusion in these indices is expected to increase DBV Technologies' visibility among the French and broader European investment communities [2].